| Year |
Citation |
Score |
| 2021 |
Yin L, Zeng Y, Zeng R, Chen Y, Wang TL, Rodabaugh KJ, Yu F, Natarajan A, Karpf AR, Dong J. Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer. Oncogene. PMID 34799660 DOI: 10.1038/s41388-021-02117-5 |
0.378 |
|
| 2021 |
Rana S, Mallareddy JR, Singh S, Boghean L, Natarajan A. Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase. Cancers. 13. PMID 34771669 DOI: 10.3390/cancers13215506 |
0.611 |
|
| 2020 |
Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S, Sonawane Y, Neilsen BK, Taylor M, Kizhake S, Thakare RN, Chowdhury S, Wang J, Black JD, Hollingsworth MA, ... ... Natarajan A, et al. Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 11: 2462-2463. PMID 32637035 DOI: 10.18632/Oncotarget.27403 |
0.775 |
|
| 2020 |
Rana S, Kour S, Sonawane YA, Robb CM, Contreras JI, Kizhake S, Zahid M, Karpf AR, Natarajan A. Symbiotic Prodrugs (SymProDs) Dual Targeting of NFkappaB and CDK. Chemical Biology & Drug Design. PMID 32237047 DOI: 10.1111/Cbdd.13684 |
0.805 |
|
| 2020 |
Tom EC, Mushtaq I, Mohapatra BC, Luan H, Bhat AM, Zutshi N, Chakraborty S, Islam N, Arya P, Bielecki TA, Iseka FM, Bhattacharyya S, Cypher LR, Goetz BT, Negi SK, ... ... Natarajan A, et al. EHD1 and RUSC2 control basal EGFR cell surface expression and recycling. Molecular and Cellular Biology. PMID 31932478 DOI: 10.1128/Mcb.00434-19 |
0.591 |
|
| 2019 |
Ahmed A, Boulton S, Shao H, Akimoto M, Natarajan A, Cheng X, Melacini G. Recent Advances in EPAC-Targeted Therapies: A Biophysical Perspective. Cells. 8. PMID 31752286 DOI: 10.3390/Cells8111462 |
0.43 |
|
| 2019 |
Zheng XF, Acharya SS, Choe KN, Nikhil K, Adelmant G, Satapathy SR, Sharma S, Viccaro K, Rana S, Natarajan A, Sicinski P, Marto JA, Shah K, Chowdhury D. A mitotic CDK5-PP4 phospho-signaling cascade primes 53BP1 for DNA repair in G1. Nature Communications. 10: 4252. PMID 31534152 DOI: 10.1038/S41467-019-12084-X |
0.561 |
|
| 2019 |
Kour S, Rana S, Contreras JI, King HM, Robb CM, Sonawane YA, Bendjennat M, Crawford AJ, Barger CJ, Kizhake S, Luo X, Hollingsworth MA, Natarajan A. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Molecular Pharmacology. 96: 419-429. PMID 31467029 DOI: 10.1124/Mol.119.116855 |
0.808 |
|
| 2019 |
Rana S, Bendjennat M, Kour S, King HM, Kizhake S, Zahid M, Natarajan A. Selective degradation of CDK6 by a palbociclib based PROTAC. Bioorganic & Medicinal Chemistry Letters. PMID 30935795 DOI: 10.1016/J.Bmcl.2019.03.035 |
0.804 |
|
| 2019 |
Al-Mugotir M, Kolar C, Vance K, Kelly DL, Natarajan A, Borgstahl GEO. A simple fluorescent assay for the discovery of protein-protein interaction inhibitors. Analytical Biochemistry. PMID 30707898 DOI: 10.1016/J.Ab.2019.01.010 |
0.331 |
|
| 2018 |
Rana S, Sonawane YA, Taylor MA, Kizhake S, Zahid M, Natarajan A. Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy. Bioorganic & Medicinal Chemistry Letters. PMID 30343954 DOI: 10.1016/J.Bmcl.2018.10.020 |
0.823 |
|
| 2018 |
Contreras JI, Robb CM, King HM, Baxter J, Crawford AJ, Kour S, Kizhake S, Sonawane YA, Rana S, Hollingsworth MA, Luo X, Natarajan A. Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy. Acs Chemical Biology. PMID 29608269 DOI: 10.1021/Acschembio.8B00077 |
0.799 |
|
| 2018 |
Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S, Sonawane Y, Neilsen BK, Taylor M, Kizhake S, Thakare RN, Chowdhury S, Wang J, Black JD, Hollingsworth MA, ... ... Natarajan A, et al. Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 9: 5216-5232. PMID 29435174 DOI: 10.18632/Oncotarget.23749 |
0.815 |
|
| 2018 |
Kumar B, Ahmad R, Rana S, Natarajan A, Dhawan P, Singh AB. Abstract 1350: Inhibiting VPS34 suppresses Wnt/beta-catenin signaling and promotes chemotherapeutic efficacy in colon cancer cells Cancer Research. 78: 1350-1350. DOI: 10.1158/1538-7445.Am2018-1350 |
0.68 |
|
| 2017 |
Sonawane YA, Zhu Y, Garrison JC, Ezell EL, Zahid M, Cheng X, Natarajan A. Structure-Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors. Acs Medicinal Chemistry Letters. 8: 1183-1187. PMID 29375750 DOI: 10.1021/Acsmedchemlett.7B00358 |
0.413 |
|
| 2017 |
Bhattacharya D, Svechkarev D, Souchek JJ, Hill TK, Taylor MA, Natarajan A, Mohs AM. Impact of structurally modifying hyaluronic acid on CD44 interaction. Journal of Materials Chemistry. B. 5: 8183-8192. PMID 29354263 DOI: 10.1039/C7Tb01895A |
0.714 |
|
| 2017 |
Abid M, A Sonawane Y, I Contreras J, Rana S, Natarajan A. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation protein. Current Medicinal Chemistry. PMID 28901269 DOI: 10.2174/0929867324666170912092659 |
0.673 |
|
| 2017 |
Robb CM, Contreras JI, Kour S, Taylor MA, Abid M, Sonawane YA, Zahid M, Murry DJ, Natarajan A, Rana S. Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chemical Communications (Cambridge, England). PMID 28636052 DOI: 10.1039/C7Cc03879H |
0.793 |
|
| 2017 |
Yefidoff-Freedman R, Fan J, Yan L, Zhang Q, Dos Santos GRRM, Rana S, Contreras JI, Sahoo R, Wan D, Yang J, Dias-Teixeira KL, Morisseau C, Du R, Halperin JA, Hammock BD, ... Natarajan A, et al. Development of 1-((1,4-trans)-4-aryloxycyclohexyl)-3-arylurea Activators of the Heme Regulated Inhibitor as Selective Activators of Eucaryotic Translation Initiation Factor 2 Alpha (eIF2α) Phosphorylation Arm of the Integrated Endoplasmic Reticulum Stress Response. Journal of Medicinal Chemistry. PMID 28590739 DOI: 10.1021/Acs.Jmedchem.7B00059 |
0.79 |
|
| 2017 |
Arnst JL, Hein AL, Taylor MA, Palermo NY, Contreras JI, Sonawane YA, Wahl AO, Ouellette MM, Natarajan A, Yan Y. Discovery and characterization of small molecule Rac1 inhibitors. Oncotarget. PMID 28410221 DOI: 10.18632/Oncotarget.16656 |
0.816 |
|
| 2016 |
You W, Huang YM, Kizhake S, Natarajan A, Chang CA. Characterization of Promiscuous Binding of Phosphor Ligands to Breast-Cancer-Gene 1 (BRCA1) C-Terminal (BRCT): Molecular Dynamics, Free Energy, Entropy and Inhibitor Design. Plos Computational Biology. 12: e1005057. PMID 27560145 DOI: 10.1371/Journal.Pcbi.1005057 |
0.406 |
|
| 2016 |
Hein AL, Post CM, Sheinin YM, Lakshmanan I, Natarajan A, Enke CA, Batra SK, Ouellette MM, Yan Y. RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment. Oncogene. PMID 27181206 DOI: 10.1038/Onc.2016.163 |
0.462 |
|
| 2016 |
Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A. Cyclin dependent kinase 9 inhibitors for cancer therapy. Journal of Medicinal Chemistry. PMID 27171036 DOI: 10.1021/Acs.Jmedchem.6B00150 |
0.839 |
|
| 2016 |
Rana S, Blowers EC, Tebbe C, Contreras JI, Radhakrishnan P, Kizhake S, Zhou T, Rajule RN, Arnst J, Munkarah AR, Rattan R, Natarajan A. Isatin derived spirocyclic analogs with α-methylene-γ-butyrolactone as anticancer agents: A structure activity rela-tionship study. Journal of Medicinal Chemistry. PMID 27077228 DOI: 10.1021/Acs.Jmedchem.6B00400 |
0.782 |
|
| 2016 |
Pessetto ZY, Yan Y, Bessho T, Natarajan A. Erratum to: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Breast Cancer Research and Treatment. PMID 26883325 DOI: 10.1007/S10549-016-3702-6 |
0.774 |
|
| 2015 |
Maroni D, Rana S, Mukhopadhyay C, Natarajan A, Naramura M. A quinoxaline urea analog uncouples inflammatory and pro-survival functions of IKKβ. Immunology Letters. PMID 26518140 DOI: 10.1016/J.Imlet.2015.10.011 |
0.649 |
|
| 2015 |
Mundra V, Peng Y, Rana S, Natarajan A, Mahato RI. Micellar formulation of indocyanine green for phototherapy of melanoma. Journal of Controlled Release : Official Journal of the Controlled Release Society. 220: 130-140. PMID 26482083 DOI: 10.1016/J.Jconrel.2015.10.029 |
0.524 |
|
| 2015 |
Gautam N, Thakare R, Rana S, Natarajan A, Alnouti Y. Irreversible binding of an anticancer compound (BI-94) to plasma proteins. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-16. PMID 25869245 DOI: 10.3109/00498254.2015.1025250 |
0.522 |
|
| 2015 |
Rana S, Blowers EC, Natarajan A. Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases. Journal of Medicinal Chemistry. 58: 2-29. PMID 25122135 DOI: 10.1021/Jm401994C |
0.786 |
|
| 2015 |
Rana S, Blowers E, Natarajan A. Abstract 3645: A non-ATP competitive IKKβ inhibitor for cancer therapy Cancer Research. 75: 3645-3645. DOI: 10.1158/1538-7445.Am2015-3645 |
0.83 |
|
| 2014 |
Bailey TA, Luan H, Tom E, Bielecki TA, Mohapatra B, Ahmad G, George M, Kelly DL, Natarajan A, Raja SM, Band V, Band H. A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells. The Journal of Biological Chemistry. 289: 30443-58. PMID 25225290 DOI: 10.1074/Jbc.M114.608992 |
0.507 |
|
| 2013 |
Chen T, Takrouri K, Hee-Hwang S, Rana S, Yefidoff-Freedman R, Halperin J, Natarajan A, Morisseau C, Hammock B, Chorev M, Aktas BH. Explorations of substituted urea functionality for the discovery of new activators of the heme-regulated inhibitor kinase. Journal of Medicinal Chemistry. 56: 9457-70. PMID 24261904 DOI: 10.1021/Jm400793V |
0.606 |
|
| 2013 |
Chaturvedi NK, Rajule RN, Shukla A, Radhakrishnan P, Todd GL, Natarajan A, Vose JM, Joshi SS. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach. Molecular Cancer Therapeutics. 12: 2006-17. PMID 23963361 DOI: 10.1158/1535-7163.Mct-13-0239 |
0.415 |
|
| 2013 |
Arnst JL, Davies CW, Raja SM, Das C, Natarajan A. High-throughput compatible fluorescence resonance energy transfer-based assay to identify small molecule inhibitors of AMSH deubiquitinase activity. Analytical Biochemistry. 440: 71-7. PMID 23747283 DOI: 10.1016/J.Ab.2013.05.017 |
0.8 |
|
| 2013 |
Kumar EA, Chen Q, Kizhake S, Kolar C, Kang M, Chang CE, Borgstahl GE, Natarajan A. The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides. Scientific Reports. 3: 1639. PMID 23572190 DOI: 10.1038/Srep01639 |
0.764 |
|
| 2013 |
Radhakrishnan P, Bryant VC, Blowers EC, Rajule RN, Gautam N, Anwar MM, Mohr AM, Grandgenett PM, Bunt SK, Arnst JL, Lele SM, Alnouti Y, Hollingsworth MA, Natarajan A. Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2025-35. PMID 23444213 DOI: 10.1158/1078-0432.Ccr-12-2909 |
0.767 |
|
| 2013 |
Rana S, Natarajan A. Face selective reduction of the exocyclic double bond in isatin derived spirocyclic lactones. Organic & Biomolecular Chemistry. 11: 244-7. PMID 23160888 DOI: 10.1039/C2Ob27008K |
0.507 |
|
| 2013 |
Mohapatra B, Ahmad G, Nadeau S, Zutshi N, An W, Scheffe S, Dong L, Feng D, Goetz B, Arya P, Bailey TA, Palermo N, Borgstahl GE, Natarajan A, Raja SM, et al. Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochimica Et Biophysica Acta. 1833: 122-39. PMID 23085373 DOI: 10.1016/J.Bbamcr.2012.10.010 |
0.388 |
|
| 2012 |
Pessetto ZY, Yan Y, Bessho T, Natarajan A. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Breast Cancer Research and Treatment. 134: 511-7. PMID 22562176 DOI: 10.1007/S10549-012-2079-4 |
0.784 |
|
| 2012 |
Kumar EA, Yuan Z, Palermo NY, Dong L, Ahmad G, Lokesh GL, Kolar C, Kizhake S, Borgstahl GE, Band H, Natarajan A. Peptide truncation leads to a twist and an unusual increase in affinity for casitas B-lineage lymphoma tyrosine kinase binding domain. Journal of Medicinal Chemistry. 55: 3583-7. PMID 22394513 DOI: 10.1021/Jm300078Z |
0.789 |
|
| 2012 |
Rajule R, Bryant VC, Lopez H, Luo X, Natarajan A. Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study. Bioorganic & Medicinal Chemistry. 20: 2227-34. PMID 22386982 DOI: 10.1016/J.Bmc.2012.02.022 |
0.801 |
|
| 2012 |
Bryant VC, Kishore Kumar GD, Nyong AM, Natarajan A. Synthesis and evaluation of macrocyclic diarylether heptanoid natural products and their analogs. Bioorganic & Medicinal Chemistry Letters. 22: 245-8. PMID 22137846 DOI: 10.1016/J.Bmcl.2011.11.025 |
0.804 |
|
| 2012 |
Chaturvedi NK, Rajule R, Ashima S, Radhakrishnan P, Natarajan A, Vose JM, Joshi SS. Novel Treatment for Therapy-Resistant Mantle Cell Lymphoma Targeting NF-κB and mTOR Signaling Pathways in Vitro and in Vivo Blood. 120: 63-63. DOI: 10.1182/Blood.V120.21.63.63 |
0.421 |
|
| 2011 |
Anisimov VM, Ziemys A, Kizhake S, Yuan Z, Natarajan A, Cavasotto CN. Computational and experimental studies of the interaction between phospho-peptides and the C-terminal domain of BRCA1. Journal of Computer-Aided Molecular Design. 25: 1071-84. PMID 22086652 DOI: 10.1007/S10822-011-9484-3 |
0.308 |
|
| 2011 |
Yuan Z, Kumar EA, Campbell SJ, Palermo NY, Kizhake S, Mark Glover JN, Natarajan A. Exploiting the P-1 pocket of BRCT domains toward a structure guided inhibitor design. Acs Medicinal Chemistry Letters. 2: 764-767. PMID 22046493 DOI: 10.1021/Ml200147A |
0.796 |
|
| 2011 |
Yuan Z, Kumar EA, Kizhake S, Natarajan A. Structure-activity relationship studies to probe the phosphoprotein binding site on the carboxy terminal domains of the breast cancer susceptibility gene 1. Journal of Medicinal Chemistry. 54: 4264-8. PMID 21574625 DOI: 10.1021/Jm1016413 |
0.801 |
|
| 2011 |
Naramura M, Nadeau S, Mohapatra B, Ahmad G, Mukhopadhyay C, Sattler M, Raja SM, Natarajan A, Band V, Band H. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget. 2: 245-50. PMID 21422499 DOI: 10.18632/Oncotarget.233 |
0.336 |
|
| 2011 |
Chen Q, Bryant VC, Lopez H, Kelly DL, Luo X, Natarajan A. 2,3-Substituted quinoxalin-6-amine analogs as antiproliferatives: a structure-activity relationship study. Bioorganic & Medicinal Chemistry Letters. 21: 1929-32. PMID 21376584 DOI: 10.1016/J.Bmcl.2011.02.055 |
0.812 |
|
| 2011 |
Kumar EA, Charvet CD, Lokesh GL, Natarajan A. High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions. Analytical Biochemistry. 411: 254-60. PMID 21129358 DOI: 10.1016/J.Ab.2010.11.038 |
0.829 |
|
| 2011 |
Raja SM, Clubb RJ, Ortega-Cava C, Williams SH, Bailey TA, Duan L, Zhao X, Reddi AL, Nyong AM, Natarajan A, Band V, Band H. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biology & Therapy. 11: 263-76. PMID 21088503 DOI: 10.4161/Cbt.11.2.13959 |
0.464 |
|
| 2010 |
Joseph PR, Yuan Z, Kumar EA, Lokesh GL, Kizhake S, Rajarathnam K, Natarajan A. Structural characterization of BRCT-tetrapeptide binding interactions. Biochemical and Biophysical Research Communications. 393: 207-10. PMID 20122900 DOI: 10.1016/J.Bbrc.2010.01.098 |
0.776 |
|
| 2008 |
Simeonov A, Yasgar A, Jadhav A, Lokesh GL, Klumpp C, Michael S, Austin CP, Natarajan A, Inglese J. Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction. Analytical Biochemistry. 375: 60-70. PMID 18158907 DOI: 10.1016/J.Ab.2007.11.039 |
0.419 |
|
| 2007 |
Lory PM, Estrella-Jimenez ME, Shashack MJ, Lokesh GL, Natarajan A, Gilbertson SR. Synthesis and screening of 3-substituted thioxanthen-9-one-10,10-dioxides. Bioorganic & Medicinal Chemistry Letters. 17: 5940-3. PMID 17826998 DOI: 10.1016/J.Bmcl.2007.07.103 |
0.398 |
|
| 2007 |
Lokesh GL, Muralidhara BK, Negi SS, Natarajan A. Thermodynamics of phosphopeptide tethering to BRCT: the structural minima for inhibitor design. Journal of the American Chemical Society. 129: 10658-9. PMID 17685618 DOI: 10.1021/Ja0739178 |
0.428 |
|
| 2006 |
Ganorkar R, Natarajan A, Mamai A, Madalengoitia JS. Synthesis of conformationally constrained lysine analogues. The Journal of Organic Chemistry. 71: 5004-7. PMID 16776535 DOI: 10.1021/Jo060210F |
0.699 |
|
| 2006 |
Lokesh GL, Rachamallu A, Kumar GD, Natarajan A. High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1. Analytical Biochemistry. 352: 135-41. PMID 16500609 DOI: 10.1016/J.Ab.2006.01.025 |
0.435 |
|
| 2005 |
Zhang R, Nicki CK, Marnai A, Flemer S, Natarajan A, Dostmann WR, Madalengoitia JS. Poly-L-proline type II peptide mimics as probes of the active site occupancy requirements of cGMP-dependent protein kinase Journal of Peptide Research. 66: 151-159. PMID 16138853 DOI: 10.1111/J.1399-3011.2005.00280.X |
0.738 |
|
| 2004 |
Natarajan A, Guo Y, Harbinski F, Fan YH, Chen H, Luus L, Diercks J, Aktas H, Chorev M, Halperin JA. Novel arylsulfoanilide-oxindole hybrid as an anticancer agent that inhibits translation initiation. Journal of Medicinal Chemistry. 47: 4979-82. PMID 15456240 DOI: 10.1021/Jm0496234 |
0.439 |
|
| 2004 |
Chen H, Fan YH, Natarajan A, Guo Y, Iyasere J, Harbinski F, Luus L, Christ W, Aktas H, Halperin JA. Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation. Bioorganic & Medicinal Chemistry Letters. 14: 5401-5. PMID 15454234 DOI: 10.1016/J.Bmcl.2004.08.017 |
0.454 |
|
| 2004 |
Natarajan A, Moerke N, Fan YH, Chen H, Christ WJ, Wagner G, Halperin JA. Synthesis of fluorescein labeled 7-methylguanosinemonophosphate. Bioorganic & Medicinal Chemistry Letters. 14: 2657-60. PMID 15109672 DOI: 10.1016/J.Bmcl.2004.02.090 |
0.308 |
|
| 2004 |
Fan YH, Chen H, Natarajan A, Guo Y, Harbinski F, Iyasere J, Christ W, Aktas H, Halperin JA. Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium. Bioorganic & Medicinal Chemistry Letters. 14: 2547-50. PMID 15109648 DOI: 10.1016/J.Bmcl.2004.02.087 |
0.305 |
|
| 2004 |
Natarajan A, Fan YH, Chen H, Guo Y, Iyasere J, Harbinski F, Christ WJ, Aktas H, Halperin JA. 3,3-diaryl-1,3-dihydroindol-2-ones as antiproliferatives mediated by translation initiation inhibition. Journal of Medicinal Chemistry. 47: 1882-5. PMID 15055987 DOI: 10.1021/Jm0499716 |
0.392 |
|
| Show low-probability matches. |